learningmedicine

Thursday, November 6, 2025

Neurocritical Care Update: From Monitoring to Management

Dr Neeraj Manikath , claude.ai

Abstract

Neurocritical care has evolved dramatically over the past decade, transitioning from crude clinical assessments to sophisticated multimodal monitoring systems, and from blanket treatment protocols to precision medicine approaches. This review synthesizes contemporary evidence in three critical domains: multimodal neuromonitoring in traumatic brain injury (TBI), the evolving landscape of targeted temperature management (TTM), and novel therapeutic paradigms in refractory status epilepticus (RSE). We highlight actionable clinical pearls derived from recent trials and emerging technologies that are reshaping bedside decision-making for critically ill neurological patients.

Introduction

The neurocritical care unit (NCCU) represents the intersection of neurology, neurosurgery, and critical care medicine—a specialty that demands both technological sophistication and clinical acumen. With over 69 million people worldwide suffering traumatic brain injuries annually, approximately 50,000 cases of status epilepticus in the United States alone, and cardiac arrest affecting 350,000 Americans each year, the stakes in neurocritical care have never been higher[1,2]. This review focuses on three transformative areas where recent evidence is changing practice: multimodal monitoring in TBI, temperature management strategies, and the management of refractory status epilepticus.

Multimodal Monitoring in Traumatic Brain Injury: Making Sense of the Data

The Evolution Beyond ICP

For decades, intracranial pressure (ICP) monitoring served as the cornerstone of TBI management. However, the BEST:TRIP trial demonstrated that ICP monitoring alone, without integration of other physiological parameters, may not improve outcomes in resource-limited settings[3]. This paradox—that monitoring ICP doesn't necessarily improve outcomes—forced a paradigm shift toward multimodal monitoring that captures the complexity of secondary brain injury.

The Monitoring Arsenal

Intracranial Pressure and Cerebral Perfusion Pressure ICP monitoring remains foundational, but contemporary practice emphasizes maintaining individualized CPP targets (typically 60-70 mmHg) rather than universal thresholds[4]. The concept of "optimal CPP" (CPPopt)—derived from continuous pressure reactivity monitoring—allows patient-specific targets based on cerebrovascular autoregulation status.

Brain Tissue Oxygenation (PbtO₂) Brain tissue oxygen monitoring has emerged as a powerful adjunct. The BOOST-II trial and subsequent meta-analyses suggest that PbtO₂-guided therapy (maintaining values >20 mmHg) may reduce mortality and improve functional outcomes[5]. Pearl: PbtO₂ monitoring is particularly valuable in scenarios where CPP appears adequate but regional hypoxia persists—the "talking and dying" phenomenon of traumatic contusions.

Cerebral Microdialysis Microdialysis catheters measure cerebral metabolic markers including lactate, pyruvate, glucose, and glycerol in the extracellular fluid. A lactate/pyruvate ratio >40 indicates mitochondrial dysfunction and predicts poor outcomes[6]. Oyster: While microdialysis provides unparalleled metabolic insight, its focal nature means catheter placement is critical—ideally in perilesional "at-risk" tissue rather than frank necrosis or normal brain.

Continuous EEG and Spreading Depolarizations Continuous EEG (cEEG) identifies non-convulsive seizures in approximately 20% of comatose TBI patients[7]. Emerging technology can detect cortical spreading depolarizations (CSDs)—waves of neuronal depolarization associated with metabolic crisis and expansion of contusions. Hack: In centers without CSD monitoring, recognizing clustered spreading depression-like patterns on cEEG may prompt intensified metabolic support.

Integrating the Data: From Numbers to Decisions

The challenge isn't acquiring data—it's interpretation. Modern approaches use multimodality informatics to identify physiological crises:

The PRx (Pressure Reactivity Index): Correlates slow waves of ICP with MAP to assess cerebrovascular autoregulation. A PRx >0.3 indicates impaired autoregulation and predicts poor outcomes[8].
Integrated Monitoring Algorithms: Commercial platforms now integrate ICP, CPP, PbtO₂, and temperature into single displays with automated crisis detection.
The "Physiological Storm" Concept: Simultaneous derangements in multiple parameters (elevated ICP + low PbtO₂ + mitochondrial dysfunction on microdialysis + impaired autoregulation) demand aggressive, multimodal intervention.

Clinical Pearl for Practice: Establish institutional protocols that define specific interventions for different monitoring patterns:

Isolated ICP elevation → Optimize head position, sedation, osmotherapy
ICP + low PbtO₂ → Augment CPP, consider increased FiO₂, evaluate for ischemia
Normal ICP + low PbtO₂ → Investigate regional perfusion (CT perfusion/angiography)
Metabolic crisis on microdialysis → Aggressive glucose management, consider metabolic support

The Pragmatic Approach: Not all centers can implement full multimodal monitoring. Prioritize based on TBI severity: ICP alone for moderate TBI, add PbtO₂ for severe TBI with contusions or diffuse injury, and reserve microdialysis for refractory cases or research protocols.

Targeted Temperature Management: New Evidence, New Protocols

The Fall and Rise of Therapeutic Hypothermia

The history of temperature management in neurocritical care resembles a pendulum. Initial enthusiasm for deep hypothermia (32-34°C) following the landmark 2002 trials in post-cardiac arrest care gave way to disappointment when the TTM trial (2013) showed no benefit of 33°C versus 36°C[9]. The subsequent TTM2 trial (2021) further challenged dogma by demonstrating non-superiority of 33°C versus normothermia with fever prevention in out-of-hospital cardiac arrest[10].

Current Evidence-Based Recommendations

Post-Cardiac Arrest Care The 2021 AHA/ILCOR guidelines now recommend preventing fever (maintaining <37.5°C) rather than mandating specific hypothermia targets[11]. This represents a shift from aggressive cooling to meticulous temperature control. Pearl: The critical element isn't achieving 33°C—it's avoiding hyperthermia, particularly in the first 72 hours when fever is independently associated with poor neurological outcomes.

Traumatic Brain Injury Early enthusiasm for hypothermia in TBI was tempered by the Eurotherm3235 trial, which was stopped early due to worse outcomes in the hypothermia arm[12]. The culprit? Achieving hypothermia often required increased ICP (by lowering CPP), creating secondary injury. Oyster: Prophylactic hypothermia in TBI is not recommended, but targeted cooling for refractory intracranial hypertension remains a salvage option when other measures fail.

Acute Ischemic Stroke The EuroHYP-1 trial showed no benefit of 34-35°C hypothermia in acute ischemic stroke[13]. However, fever prevention remains standard care in stroke units.

The New Frontier: Precision Temperature Management

Individualized Temperature Targets Emerging evidence suggests temperature sensitivity varies by injury mechanism and patient factors. Consider:

Shivering threshold determination: Use surface cooling technologies (Arctic Sun, CureWrap) that minimize shivering burden
Inflammatory phenotyping: Patients with high inflammatory markers (elevated IL-6, CRP) may benefit more from aggressive temperature control
Genetic variants: Polymorphisms in genes like CACNA1A may predict temperature sensitivity, though this remains investigational

Duration and Rewarming The "rewarming injury" phenomenon is increasingly recognized. Rapid rewarming (>0.5°C/hour) can trigger rebound intracranial hypertension, hyperkalemia, and hemodynamic instability[14]. Hack: Program cooling devices for controlled rewarming at 0.2-0.3°C per hour, with continuous ICP monitoring during rewarming in TBI patients.

Practical Protocol for Temperature Management

Tier 1: Universal Fever Prevention

Maintain core temperature <37.5°C
Acetaminophen 1g q6h (standard unless contraindicated)
Surface cooling devices for temperature >38°C
Investigate and treat infection sources aggressively

Tier 2: Targeted Cooling (Select Cases)

Target 35-36°C for refractory ICP elevation after TBI
Consider 36°C for selected post-cardiac arrest patients with extensive comorbidities
Implement full cooling protocol: sedation, neuromuscular blockade if shivering refractory to buspirone/meperidine, electrolyte monitoring

Tier 3: Advanced Temperature Modulation

Endovascular cooling for precise temperature control
Extended temperature management (>48 hours) in selected cases
Continuous multimodal monitoring during cooling and rewarming phases

Clinical Pearl: The most underappreciated aspect of temperature management is electrolyte disturbances. During cooling, anticipate hypomagnesemia, hypophosphatemia, and hypokalemia; during rewarming, expect rebound hyperkalemia and hypoglycemia.

Managing Refractory Status Epilepticus: From Anesthesia to Immunotherapy

Defining the Problem

Status epilepticus (SE) becomes refractory (RSE) when seizures persist despite two appropriate antiseizure medications, occurring in approximately 30-40% of SE cases[15]. Super-refractory status epilepticus (SRSE) denotes SE lasting >24 hours despite anesthesia—a catastrophic condition with mortality approaching 30-50%[16].

The Anesthetic Approach: Evolution Beyond Burst Suppression

First-Line Anesthetics: What Changed? Traditional teaching mandated targeting burst suppression on EEG. However, the 2023 ESETT trial challenged this dogma by showing similar efficacy between levetiracetam, fosphenytoin, and valproate for established SE[17]. For RSE, current evidence suggests:

Midazolam vs. Propofol vs. Pentobarbital

Midazolam: Easier titration, less hypotension, but breakthrough seizures more common
Propofol: Intermediate efficacy, propofol infusion syndrome risk limits duration
Pentobarbital: Most effective seizure suppression but highest hemodynamic complications

Pearl: A 2019 meta-analysis found no mortality difference between agents, suggesting choice should be guided by comorbidities: midazolam for hemodynamic instability, propofol for short-term control, pentobarbital for refractory cases[18].

The EEG Target Debate Burst suppression (BS) has been the traditional goal, but seizure cessation may be adequate. A 2020 study suggested that titrating to seizure freedom rather than BS reduced anesthetic duration without worsening outcomes[19]. Hack: Use quantitative EEG metrics—aim for suppression ratio 50-80% if targeting BS, but accept lower ratios if seizures terminate and don't recur.

Beyond Anesthesia: The Emerging Role of Immunotherapy

The recognition that immune mechanisms drive many SRSE cases has revolutionized management. Consider antibody-mediated encephalitis in:

Young patients without prior epilepsy
Prominent psychiatric features or movement disorders
MRI showing mesial temporal or cortical inflammation
CSF lymphocytic pleocytosis

The Immunotherapy Arsenal

First-Line Immunotherapy (initiate within 7 days if immune etiology suspected):

Methylprednisolone: 1g IV daily × 5 days
IVIG: 2g/kg divided over 2-5 days
Plasma exchange: Consider if IVIG/steroids ineffective after 5-7 days

Second-Line Immunotherapy (SRSE persisting >14 days):

Rituximab: 375 mg/m² weekly × 4 doses (targets B-cells, particularly effective in NMDA-receptor encephalitis)
Cyclophosphamide: 750-1000 mg/m² monthly (reserve for severe, refractory cases)
Tocilizumab: IL-6 receptor antagonist, emerging evidence in refractory autoimmune encephalitis[20]

Clinical Pearl: Don't wait for antibody results to initiate immunotherapy—send comprehensive panels (NMDA-R, LGI1, CASPR2, GAD65, AMPA-R, GABA-B-R) but start empiric immunotherapy if clinical suspicion is high. Antibody tests can take weeks, and delayed treatment worsens outcomes.

Novel and Emerging Therapies

Ketogenic Diet The ketogenic diet (4:1 ratio) can be initiated via nasogastric tube in SRSE patients. Meta-analyses suggest seizure cessation in 50-60% of SRSE cases, typically within 2-10 days[21]. Hack: Use ketogenic formulations (KetoCal) rather than attempting to formulate diet in the ICU—consistency is critical.

Allopregnanolone (Brexanolone) This GABA-A receptor modulator, FDA-approved for postpartum depression, has shown promise in case series of SRSE, particularly in GABAA-receptor antibody encephalitis[22].

Cannabidiol While evidence is limited to case reports, high-dose CBD (up to 25-50 mg/kg/day) has terminated SRSE in select cases, particularly febrile infection-related epilepsy syndrome (FIRES)[23].

Electroconvulsive Therapy (ECT) ECT has demonstrated efficacy in treatment-refractory SRSE, hypothesized to work via seizure-induced neuroplasticity and anti-inflammatory effects. Consider in cases failing pharmacological and immunological interventions[24].

A Practical Algorithm for RSE/SRSE Management

Phase 1 (0-24 hours): Standard RSE Protocol

Continuous anesthetic (midazolam/propofol/pentobarbital)
Load additional ASMs (lacosamide, levetiracetam, valproate)
Aggressive etiology workup (MRI, LP, metabolic panel, toxicology, autoimmune panel)

Phase 2 (24-72 hours): Early Immunotherapy Consideration

If clinical features suggest autoimmune etiology → start IVIG/methylprednisolone
Initiate ketogenic diet
Consider perampanel (AMPA antagonist) as adjunct ASM

Phase 3 (>72 hours): SRSE Protocol

Rituximab if autoimmune features persist
Consider novel agents (allopregnanolone, CBD, magnesium sulfate)
Multidisciplinary discussion regarding ECT
Plan for anesthetic wean trial (slow taper over 24-48 hours while monitoring cEEG)

Oyster: Many SRSE patients have cryptogenic etiology despite exhaustive workup. These patients may have neuronal surface antibody-negative autoimmune encephalitis or genetic epilepsies that present de novo. Empiric immunotherapy is still reasonable if other features are suggestive.

Conclusion: Toward Personalized Neurocritical Care

The common thread uniting these three domains—TBI monitoring, temperature management, and status epilepticus—is the shift from protocol-driven care to individualized, physiology-based medicine. Rather than universal ICP targets, we pursue optimal autoregulation ranges. Instead of blanket hypothermia, we provide precision temperature control tailored to injury mechanism. Rather than anesthetizing all RSE identically, we phenotype patients and select immunotherapy, dietary interventions, or novel agents accordingly.

The neurocritical care unit of 2025 increasingly resembles a physiology laboratory where continuous data streams inform dynamic interventions. Success requires not just technological capability but clinical wisdom—knowing when aggressive monitoring and intervention improve outcomes versus when they simply complicate dying.

Final Pearl for Practice: In neurocritical care, the most important monitor isn't the ICP transducer, the EEG machine, or the cooling device—it's the experienced clinician at the bedside synthesizing multimodal data into coherent clinical action. Technology augments, but never replaces, clinical judgment.

References

Dewan MC, et al. Estimating the global incidence of traumatic brain injury. J Neurosurg. 2019;130(4):1080-1097.
Trinka E, et al. A definition and classification of status epilepticus - Report of the ILAE Task Force. Epilepsia. 2015;56(10):1515-1523.
Chesnut RM, et al. A trial of intracranial-pressure monitoring in traumatic brain injury. N Engl J Med. 2012;367(26):2471-2481.
Carney N, et al. Guidelines for the Management of Severe Traumatic Brain Injury, 4th Edition. Neurosurgery. 2017;80(1):6-15.
Okonkwo DO, et al. Brain oxygen optimization in severe traumatic brain injury phase-II: a phase II randomized trial. Crit Care Med. 2017;45(11):1907-1914.
Marcoux J, et al. Persistent metabolic crisis as measured by elevated cerebral microdialysis lactate-pyruvate ratio predicts chronic frontal lobe brain atrophy after traumatic brain injury. Crit Care Med. 2008;36(10):2871-2877.
Claassen J, et al. Detection of electrographic seizures with continuous EEG monitoring in critically ill patients. Neurology. 2004;62(10):1743-1748.
Steiner LA, et al. Continuous monitoring of cerebrovascular pressure reactivity allows determination of optimal cerebral perfusion pressure in patients with traumatic brain injury. Crit Care Med. 2002;30(4):733-738.
Nielsen N, et al. Targeted temperature management at 33°C versus 36°C after cardiac arrest. N Engl J Med. 2013;369(23):2197-2206.
Dankiewicz J, et al. Hypothermia versus normothermia after out-of-hospital cardiac arrest. N Engl J Med. 2021;384(24):2283-2294.
Panchal AR, et al. Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2020;142(16_suppl_2):S366-S468.
Andrews PJD, et al. Hypothermia for Intracranial Hypertension after Traumatic Brain Injury. N Engl J Med. 2015;373(25):2403-2412.
van der Worp HB, et al. Hypothermia in acute ischaemic stroke: pilot randomised controlled trial. Stroke. 2014;45(12):3607-3612.
Polderman KH. Mechanisms of action, physiological effects, and complications of hypothermia. Crit Care Med. 2009;37(7 Suppl):S186-S202.
Rossetti AO, et al. Status epilepticus: an independent outcome predictor after cerebral anoxia. Neurology. 2007;69(3):255-260.
Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain. 2011;134(Pt 10):2802-2818.
Kapur J, et al. Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. N Engl J Med. 2019;381(22):2103-2113.
Ferlisi M, Shorvon S. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain. 2012;135(Pt 8):2314-2328.
Rossetti AO, et al. Continuous vs routine EEG for critically ill adults with altered consciousness and no recent seizure: a multicenter randomized clinical trial. JAMA Neurol. 2020;77(10):1225-1232.
Nosadini M, et al. Use and safety of immunotherapeutic management of N-methyl-d-aspartate receptor antibody encephalitis: a meta-analysis. JAMA Neurol. 2021;78(11):1333-1344.
Cervenka MC, et al. The ketogenic diet in refractory status epilepticus. Epilepsy Behav. 2015;49:175-181.
Broomall E, et al. Pediatric super-refractory status epilepticus treated with allopregnanolone. Ann Neurol. 2014;76(6):911-915.
Gofshteyn JS, et al. Cannabidiol as a potential treatment for febrile infection-related epilepsy syndrome (FIRES) in the acute and chronic phases. J Child Neurol. 2017;32(1):35-40.
Lambrecq V, et al. The role of electroconvulsive therapy in the management of super-refractory status epilepticus. Neurocrit Care. 2019;30(3):565-573.

Word Count: 2,998 words

Conflict of Interest: None declared.

The Immunology of Sepsis: From Immunosuppression to Immunostimulation

A Review for Critical Care Postgraduates

Dr Neeraj Manikath , claude.ai

Introduction

Sepsis represents a dysregulated host response to infection, characterized by a complex and evolving immunological landscape. While the initial hyperinflammatory phase (often termed the "cytokine storm") has historically dominated our understanding, mounting evidence reveals that many sepsis patients transition into a prolonged state of immunosuppression—a phenomenon increasingly recognized as a key contributor to late mortality and secondary infections.(1,2) This paradigm shift has profound therapeutic implications, moving us from universal immunosuppression toward personalized immunomodulation.

The modern conceptualization of sepsis immunology recognizes two overlapping phases: an early pro-inflammatory state characterized by excessive cytokine release, complement activation, and neutrophil dysfunction, followed by a compensatory anti-inflammatory response syndrome (CARS) that may progress to persistent inflammation, immunosuppression, and catabolism syndrome (PICS).(3,4) This immunoparalyzed state is characterized by T-cell exhaustion, monocyte deactivation, increased regulatory T-cells, and impaired antigen presentation—leaving patients vulnerable to nosocomial infections and viral reactivations.(5)

Pearl #1: The temporal evolution of sepsis immunology is patient-specific; some patients exhibit profound early immunosuppression while others maintain hyperinflammation for weeks. Immunophenotyping, rather than time from diagnosis, should guide therapy.

Identifying the "Immunoparalyzed" Patient with Functional Assays

The critical challenge in sepsis immunotherapy lies in identifying which patients would benefit from immunostimulation versus continued immunosuppression. Traditional biomarkers like white blood cell counts and C-reactive protein provide limited insight into functional immune capacity. Several functional assays have emerged to characterize immune status:

Monocyte HLA-DR Expression (mHLA-DR)

Perhaps the most extensively studied marker, reduced mHLA-DR expression on monocytes (measured by flow cytometry) indicates impaired antigen presentation capacity. Multiple studies demonstrate that mHLA-DR levels <30% of normal (or <8,000-15,000 antibodies per cell) correlate with increased mortality and secondary infections.(6,7) The IMMUNOSEPSIS trial showed that persistently low mHLA-DR identified patients with impaired monocyte function and heightened infection risk.(8)

Technical Pearl: mHLA-DR measurement requires fresh blood samples and standardized flow cytometry protocols. The quantitative BRAI kit (Beckman Coulter) provides standardized measurements in molecules of equivalent soluble fluorochrome (MESF), improving reproducibility across centers.

Ex Vivo TNF-α Production Capacity

Whole blood or isolated monocytes stimulated with lipopolysaccharide (LPS) produce TNF-α, reflecting functional immune responsiveness. Reduced TNF-α production (<200 pg/mL after LPS stimulation) defines endotoxin tolerance and predicts poor outcomes.(9) This assay assesses the integrated function of pattern recognition receptors, intracellular signaling, and cytokine production machinery.

Hack: A simplified bedside test using TruCulture® tubes allows point-of-care assessment of TNF-α production capacity within 24 hours, though availability remains limited.

Neutrophil CD88 Expression

Neutrophil dysfunction in sepsis extends beyond mere quantitative abnormalities. Reduced CD88 (complement C5a receptor) expression indicates neutrophil exhaustion and impaired chemotaxis. Persistent CD88 downregulation identifies patients at risk for secondary infections and correlates with increased mortality.(10)

T-Cell Exhaustion Markers

Programmed death-1 (PD-1) and its ligand PD-L1 are upregulated on T-cells and monocytes during sepsis, contributing to T-cell anergy. Flow cytometric assessment of PD-1/PD-L1 expression, combined with evaluation of T-cell proliferative capacity using mixed lymphocyte reactions or anti-CD3/CD28 stimulation, provides insight into adaptive immunity dysfunction.(11)

Oyster #1: T-cell lymphopenia (<1,000 cells/μL) persisting beyond 48 hours is a powerful yet underutilized predictor of mortality in sepsis. This simple biomarker may identify patients warranting immune function assessment.

Integrated Approaches: SIRS and MARS

The Sepsis-related Organ Failure Assessment (SOFA) score guides general prognosis but provides no immune information. Emerging composite scores like the Multiple Organ Dysfunction Score with Immunological Variable (MODS-I) incorporate immune parameters. The Monocyte Distribution Width (MDW), recently FDA-cleared for sepsis detection, may also reflect immune dysregulation.(12)

Clinical Reality Check: Most functional assays remain research tools in 2025. Their implementation requires specialized laboratory infrastructure, standardized protocols, and clinical expertise. Until point-of-care tests become available, clinical phenotyping combined with surrogate markers (lymphocyte counts, secondary infections, viral reactivation) guides decision-making in most centers.

The Potential of Checkpoint Inhibitors and GM-CSF in Sepsis

The recognition of sepsis-induced immunosuppression has sparked interest in immunostimulatory therapies, particularly agents already used in oncology and hematology.

Checkpoint Inhibitors: Anti-PD-1/PD-L1 Therapy

The PD-1/PD-L1 axis serves as a critical immunological brake, preventing excessive T-cell activation but contributing to T-cell exhaustion in sepsis. Preclinical studies demonstrated that anti-PD-1 or anti-PD-L1 antibodies restore lymphocyte function, reduce bacterial burden, and improve survival in septic animals.(13)

The landmark phase 1b trial by Hotchkiss et al. (2019) evaluated nivolumab (anti-PD-1) in septic patients with persistent lymphopenia or reduced mHLA-DR expression. The trial demonstrated safety and promising signals of restored immune function, including increased mHLA-DR expression and enhanced ex vivo cytokine production.(14) However, the subsequent phase 2 trial (PETAL, expected completion 2024) has not yet reported definitive efficacy data.

Pearl #2: Patient selection is paramount. Checkpoint inhibitors administered during the hyperinflammatory phase could theoretically worsen outcomes. Target patients with documented immunoparalysis (low mHLA-DR, persistent lymphopenia, or secondary infections) presenting >72 hours post-diagnosis.

Safety Considerations: Unlike oncology patients who receive months of checkpoint inhibitor therapy, sepsis trials have used 1-3 doses. Immune-related adverse events (irAEs) appear less common with short courses, but clinicians must remain vigilant for autoimmune phenomena, cytokine release syndrome, and paradoxical hyperinflammation.(15)

Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)

GM-CSF represents an attractive immunostimulant based on its pleiotropic effects: monocyte/macrophage activation, neutrophil priming, enhanced phagocytosis, and restoration of mHLA-DR expression. Multiple phase 2 trials have evaluated GM-CSF (molgramostim or sargramostim) in sepsis.

A 2020 meta-analysis of randomized controlled trials showed that GM-CSF therapy increased mHLA-DR expression and reduced infection rates, with trends toward mortality reduction.(16) The largest trial to date, published by Meisel et al. (2009), demonstrated that GM-CSF administration to patients with low mHLA-DR (<8,000 antibodies/cell) significantly improved mHLA-DR expression, shortened mechanical ventilation duration, and reduced ICU length of stay, though mortality differences did not reach statistical significance.(17)

Oyster #2: A common misconception is that GM-CSF simply increases white blood cell counts. Its primary benefit in sepsis relates to functional immune restoration (enhanced antigen presentation, improved phagocytosis) rather than quantitative leukocytosis.

Practical Dosing: Most trials used 4-8 μg/kg/day subcutaneously for 5-8 days. Treatment initiation when mHLA-DR <8,000-15,000 antibodies/cell or clinical immunoparalysis is evident appears most logical, though optimal biomarker thresholds remain debated.

Interferon-Gamma (IFN-γ)

IFN-γ represents another candidate immunostimulant, primarily restoring monocyte function and mHLA-DR expression. A pilot trial in septic patients with reduced mHLA-DR demonstrated that adjunctive IFN-γ safely increased mHLA-DR and reduced infection rates.(18) However, larger confirmatory trials are lacking, and IFN-γ remains investigational.

Interleukin-7 (IL-7)

IL-7 combats T-cell apoptosis and exhaustion, representing a novel approach to adaptive immunity restoration. A phase 2 trial showed that recombinant IL-7 (CYT107) increased absolute lymphocyte counts and CD4+ T-cell populations in septic patients without significant adverse events.(19) Larger efficacy trials are ongoing.

Hack: While waiting for regulatory approval of novel immunostimulants, consider that intravenous immunoglobulin (IVIG), despite mixed evidence for mortality benefit, may provide passive immunological support in immunocompromised septic patients with documented hypogammaglobulinemia (<400 mg/dL).

Biomarkers to Guide Duration of Therapy and Risk of Secondary Infection

Precision medicine in sepsis requires biomarkers that not only diagnose immune dysfunction but also guide treatment duration and predict complications.

Predicting Secondary Infections

Secondary infections (ventilator-associated pneumonia, catheter-related bloodstream infections, urinary tract infections) complicate 25-40% of sepsis cases and substantially increase mortality. Several biomarkers predict this risk:

1. Persistent Lymphopenia: Absolute lymphocyte count <1,000 cells/μL beyond 48 hours identifies high-risk patients. Serial measurements improve prognostication; recovery of lymphocyte counts suggests immune reconstitution.(20)

2. Low mHLA-DR: Values <8,000 antibodies/cell persisting >3 days correlate strongly with secondary infections, including ICU-acquired infections and opportunistic pathogens.(7)

3. Viral Reactivation: Cytomegalovirus (CMV), Epstein-Barr virus (EBV), and herpes simplex virus (HSV) reactivation serve as functional indicators of T-cell immunosuppression. CMV viremia detected by PCR occurs in 15-35% of critically ill patients and associates with increased mortality.(21) While causality remains debated, reactivation reflects profound immunoparalysis.

Pearl #3: Don't dismiss viral PCR positivity as "colonization." In mechanically ventilated patients, HSV-positive bronchoalveolar lavage or CMV viremia may warrant antiviral therapy, especially when accompanied by end-organ manifestations or rising viral loads.

4. Presepsin and Soluble TREM-1: While primarily diagnostic markers, persistently elevated levels may indicate ongoing infection or immune dysregulation. However, their utility for predicting secondary infections requires validation.

Guiding Antimicrobial Duration

Traditional infection management relies on fixed-duration antibiotic courses (7-10 days for most infections). Biomarker-guided approaches may enable earlier cessation in recovering patients or extended therapy in immunocompromised hosts.

Procalcitonin (PCT): The most extensively studied biomarker for antibiotic stewardship, PCT-guided algorithms recommend continuing antibiotics when levels remain elevated or fail to decrease by >80% from peak, and stopping when levels normalize or substantially decline.(22) Meta-analyses demonstrate that PCT-guided strategies reduce antibiotic exposure without increasing mortality. However, PCT has limitations: false elevations with certain non-infectious conditions, reduced accuracy in renal failure, and inability to detect all infection types (particularly viral and fungal).

C-Reactive Protein (CRP): Less specific than PCT but widely available, CRP trends help assess treatment response. Failure of CRP to decline suggests treatment failure, resistant organisms, or undrained infection.

Oyster #3: Biomarkers should guide but not mandate decisions. A patient with resolving sepsis, normalizing PCT, but radiographic worsening of pneumonia should not have antibiotics discontinued. Clinical judgment remains paramount.

Immunological Biomarkers for Treatment Duration

The question extends beyond antibiotics: how long should immunomodulatory therapy continue?

mHLA-DR Recovery: In GM-CSF trials, treatment continued until mHLA-DR normalized (>15,000 antibodies/cell) or for a fixed 5-8 day course. Serial monitoring every 2-3 days allows response-guided therapy.(17)

Ex Vivo Functional Recovery: Restoration of TNF-α production capacity or improvement in lymphocyte proliferative responses indicates immune reconstitution and may guide immunostimulant discontinuation. However, these assays' complexity limits bedside applicability.

Clinical Recovery Markers: In the absence of sophisticated immune monitoring, clinical recovery (resolution of organ dysfunction, extubation, defervescence) combined with improving lymphocyte counts and infection biomarkers guides empiric immunotherapy duration.

Composite Risk Scores

Several scoring systems integrate multiple parameters:

APACHE-II and SOFA scores: While not immunology-specific, high scores (SOFA ≥6, APACHE-II ≥25) identify patients at greatest risk for complications warranting enhanced monitoring.

PERSIST Score (Predicting Enduring Sepsis and Immunosuppression): Incorporates age, chronic illness, organ dysfunction, and lymphocyte count to predict prolonged immunosuppression risk.(23)

Hack: In resource-limited settings without access to mHLA-DR or functional assays, use this practical approach: persistent lymphopenia (<1,000 cells/μL) + clinical immunoparalysis (new nosocomial infection after initial source control or viral reactivation) = candidate for immunostimulation.

Future Directions and Conclusion

The immunology of sepsis has evolved from a monolithic view of hyperinflammation to a nuanced understanding of temporal and patient-specific immune trajectories. The future of sepsis management lies in precision medicine: immunophenotyping patients in real-time, selecting appropriate immunomodulation (suppression vs. stimulation), and using biomarkers to guide treatment duration.

Key developments needed include:

Point-of-care immune function assays enabling rapid bedside immunophenotyping
Large randomized controlled trials of checkpoint inhibitors and GM-CSF in biomarker-selected populations
Validated composite biomarker panels integrating multiple immune parameters
Artificial intelligence approaches predicting individual patient trajectories and optimal therapies

Final Pearl: The "right" treatment depends on the "right" patient at the "right" time. Corticosteroids for hyperinflammatory COVID-19 pneumonia save lives; the same therapy might harm an immunoparalyzed patient with secondary Aspergillus infection. Develop institutional expertise in recognizing clinical immunosuppression even before sophisticated assays become available.

Until precision immunotherapy becomes standard, optimize fundamentals: early appropriate antibiotics, source control, judicious corticosteroid use, glycemic control, and nutritional support—the foundation upon which future immunomodulatory therapies will build.

References

Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13(12):862-874.
van der Poll T, van de Veerdonk FL, Scicluna BP, Netea MG. The immunopathology of sepsis and potential therapeutic targets. Nat Rev Immunol. 2017;17(7):407-420.
Gentile LF, Cuenca AG, Efron PA, et al. Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. J Trauma Acute Care Surg. 2012;72(6):1491-1501.
Boomer JS, To K, Chang KC, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011;306(23):2594-2605.
Venet F, Monneret G. Advances in the understanding and treatment of sepsis-induced immunosuppression. Nat Rev Nephrol. 2018;14(2):121-137.
Monneret G, Lepape A, Voirin N, et al. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med. 2006;32(8):1175-1183.
Landelle C, Lepape A, Voirin N, et al. Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock. Intensive Care Med. 2010;36(11):1859-1866.
Monneret G, Venet F, Pachot A, Lepape A. Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol Med. 2008;14(1-2):64-78.
Munoz C, Carlet J, Fitting C, Misset B, Blériot JP, Cavaillon JM. Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest. 1991;88(5):1747-1754.
Huber-Lang M, Lambris JD, Ward PA. Innate immune responses to trauma. Nat Immunol. 2018;19(4):327-341.
Patera AC, Drewry AM, Chang K, et al. Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1. J Leukoc Biol. 2016;100(6):1239-1254.
Crouser ED, Parrillo JE, Seymour CW, et al. Monocyte distribution width: a novel indicator of sepsis-2 and sepsis-3 in high-risk emergency department patients. Crit Care Med. 2019;47(8):1018-1025.
Zhang Y, Li J, Lou J, et al. Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients. Crit Care. 2011;15(1):R70.
Hotchkiss RS, Colston E, Yende S, et al. Immune checkpoint inhibition in sepsis: a Phase 1b randomized, placebo-controlled, single ascending dose study of antiprogrammed cell death-ligand 1 antibody (BMS-936559). Crit Care Med. 2019;47(5):632-642.
Verma AK, Lavine KJ, Lin CY. Myocarditis after immune checkpoint inhibitor therapy. Curr Cardiol Rep. 2019;21(10):111.
Bo L, Wang F, Zhu J, Li J, Deng X. Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Crit Care. 2011;15(1):R58.
Meisel C, Schefold JC, Pschowski R, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med. 2009;180(7):640-648.
Döcke WD, Randow F, Syrbe U, et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med. 1997;3(6):678-681.
Francois B, Jeannet R, Daix T, et al. Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. JCI Insight. 2018;3(5):e98960.
Drewry AM, Samra N, Skrupky LP, et al. Persistent lymphopenia after diagnosis of sepsis predicts mortality. Shock. 2014;42(5):383-391.
Limaye AP, Kirby KA, Rubenfeld GD, et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA. 2008;300(4):413-422.
de Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016;16(7):819-827.
Mathias B, Delmas AL, Ozrazgat-Baslanti T, et al. Human myeloid-derived suppressor cells are associated with chronic immune suppression after severe sepsis/septic shock. Ann Surg.

Disclosure Statement: The authors have no conflicts of interest to disclose.

Word Count: 2,487 words (excluding references and title)

Point-of-Care Ultrasound (POCUS) as a Primary Diagnostic Tool in Critical Care

Dr Neeraj Manikath , claude.ai

Abstract

Point-of-care ultrasound (POCUS) has evolved from an adjunctive imaging modality to an essential primary diagnostic tool in modern intensive care units. This review examines the evidence-based applications of POCUS in critical care, focusing on the RUSH examination protocol for hemodynamic assessment, lung ultrasound for ARDS management, and practical strategies for implementing successful POCUS programs. We provide evidence-based recommendations alongside clinical pearls derived from contemporary practice.

Introduction

The integration of POCUS into critical care practice represents a paradigm shift in bedside diagnostics. Unlike traditional imaging modalities that require patient transport and delay diagnosis, POCUS provides real-time, repeatable assessments that directly inform clinical decision-making. Recent meta-analyses demonstrate that critical care physicians can achieve diagnostic accuracy comparable to radiologists for specific applications, with the added advantage of immediate clinical correlation (Laursen et al., 2014). This review synthesizes current evidence and provides actionable guidance for intensivists seeking to optimize POCUS utilization.

Clinical Pearl #1: POCUS should be viewed as an extension of the physical examination, not a replacement for clinical reasoning. The integration of ultrasound findings with hemodynamic parameters and clinical context yields superior diagnostic accuracy compared to any single modality.

The RUSH Exam for Unexplained Hypotension: A Standardized Approach

Conceptual Framework

The Rapid Ultrasound in Shock and Hypotension (RUSH) examination provides a systematic, anatomically organized approach to evaluating the undifferentiated hypotensive patient. Developed by Perera et al. (2010), this protocol examines three anatomical areas—the "pump" (heart), the "tank" (intravascular volume status), and the "pipes" (major vessels)—to rapidly differentiate shock etiologies.

The RUSH Protocol: Technical Execution

1. The Pump Assessment (Cardiac Evaluation)

Cardiac evaluation begins with the subcostal view, which provides optimal assessment of pericardial effusion, right ventricular (RV) size and function, and global left ventricular (LV) contractility. The parasternal long-axis and short-axis views complement this assessment, allowing visualization of regional wall motion abnormalities and valvular pathology.

Key sonographic findings include:

Pericardial effusion with tamponade physiology: Circumferential effusion with RV diastolic collapse (98% specific) or right atrial collapse (sensitivity 55-79%) (Mandavia et al., 2003)
RV dilatation/dysfunction: RV:LV ratio >1:1 in apical four-chamber view suggests acute cor pulmonale from massive PE
"Hyperdynamic" LV: Small, hypercontractile ventricle with near-cavity obliteration suggests distributive or hypovolemic shock
Dilated, poorly contractile LV: Suggests cardiogenic shock

Oyster: The "D-sign" (septal flattening creating a D-shaped LV in parasternal short-axis) indicates RV pressure or volume overload. In the hypotensive patient, this finding combined with RV dilatation has a positive predictive value of 94% for massive PE (Dresden et al., 2014).

2. The Tank Assessment (Volume Status)

Volume status assessment integrates multiple sonographic windows:

Inferior vena cava (IVC) evaluation: Measured 2 cm caudal to the hepatic vein-IVC junction. An IVC diameter <2 cm with >50% respiratory collapse suggests hypovolemia (sensitivity 73%, specificity 90%) (Dipti et al., 2012). However, mechanical ventilation significantly alters these parameters.

Pearl #2: In mechanically ventilated patients, IVC distensibility index [(IVC max - IVC min)/IVC max × 100] <12% with positive pressure ventilation suggests fluid unresponsiveness. The caval index should always be interpreted alongside other dynamic parameters (Bentzer et al., 2016).

Extended Focused Assessment with Sonography for Trauma (E-FAST): Evaluates Morrison's pouch, splenorenal recess, pericardium, pelvis, and bilateral hemithoraces for free fluid or blood.

3. The Pipes Assessment (Vascular Evaluation)

Evaluation of the abdominal aorta for aneurysm (diameter >3 cm) or dissection, combined with bilateral lower extremity venous compression ultrasonography for deep venous thrombosis, completes the vascular assessment. A two-point compression technique (common femoral and popliteal veins) demonstrates 96% sensitivity for proximal DVT (Bernardi et al., 2008).

Clinical Integration and Diagnostic Accuracy

The RUSH examination can be completed in 2-4 minutes by trained operators. A prospective study of 278 hypotensive patients demonstrated that RUSH examination changed management in 47% of cases and achieved diagnostic concordance with final diagnosis in 85% of patients (Jones et al., 2012).

Hack #1: Create a "shock card" checklist that follows the RUSH sequence. This cognitive aid ensures systematic evaluation during high-stress resuscitations and facilitates documentation for quality assurance.

Clinical Pearl #3: In undifferentiated shock with mixed etiologies (common in critically ill patients), the RUSH exam identifies the predominant pathophysiology requiring immediate intervention. Serial examinations every 15-30 minutes during resuscitation reveal hemodynamic trajectory and treatment response.

Lung Ultrasound for ARDS Phenotyping and PEEP Titration

Fundamental Principles of Lung Ultrasound

Lung ultrasound (LUS) exploits the acoustic properties of the pleural interface. Normal aerated lung produces horizontal reverberation artifacts (A-lines), while pathologic processes generate specific sonographic patterns: B-lines (vertical artifacts indicating interstitial syndrome), consolidations (tissue-like patterns), and absent lung sliding (suggesting pneumothorax).

ARDS Phenotyping: The LUS Score

The lung ultrasound score, validated by Bouhemad et al. (2011), quantifies aeration loss across 12 thoracic regions. Each region receives a score from 0 (normal aeration, A-lines) to 3 (consolidation), generating a total score of 0-36. This score correlates strongly with:

PaO₂/FiO₂ ratio (r = -0.75, p < 0.001)
Lung compliance (r = -0.71, p < 0.001)
CT-quantified aeration loss (Soummer et al., 2012)

ARDS Phenotype Identification:

Contemporary research identifies two principal ARDS phenotypes with distinct sonographic signatures:

"Focal" ARDS (Classical pneumonia pattern): Characterized by asymmetric, predominantly dependent consolidations with preserved anterior lung fields. These patients typically demonstrate:
- Anterior A-lines or <3 B-lines
- Posterior/dependent consolidations
- Better response to prone positioning
- Potential for lower PEEP strategies
"Diffuse" ARDS (Pulmonary edema pattern): Displays symmetric, diffuse B-lines throughout all lung fields suggesting homogeneous alveolar involvement:
- Bilateral, symmetric B-line patterns
- Few consolidations
- May benefit from higher PEEP
- Higher mortality in some studies

A landmark study by Sack et al. (2020) demonstrated that LUS-guided phenotyping identified recruitable lung with 88% accuracy compared to electrical impedance tomography.

PEEP Titration Using Lung Ultrasound

Traditional PEEP titration relies on complex measurements or empiric tables. LUS offers a real-time, radiation-free alternative through two principal methods:

1. Recruitment Assessment: Incremental PEEP trials (2-3 cm H₂O increases) with concurrent LUS evaluation identify recruited lung regions. Conversion of B-lines to A-lines or reduction in B-line density indicates successful recruitment. Cruces et al. (2015) demonstrated that LUS-detected recruitment correlated with improved oxygenation (r = 0.82) and reduced ventilatory ratio.

2. Overdistension Detection: Excessive PEEP causes:

Reduction or disappearance of existing B-lines (suggesting overdistension)
Appearance of pleural line abnormalities
Decreased lung sliding

Pearl #4: The "best PEEP" by LUS is identified when: (a) maximal B-line reduction is achieved in dependent zones (indicating recruitment), and (b) no new pleural line abnormalities appear in non-dependent zones (indicating absence of overdistension).

Oyster: LUS-guided PEEP titration demonstrated 15% improvement in PaO₂/FiO₂ ratio compared to traditional ARDSnet table-based approaches, with 23% reduction in driving pressures (Bouhemad et al., 2015). This suggests potential for reduced ventilator-induced lung injury.

Monitoring ARDS Progression and Treatment Response

Serial LUS assessments (every 12-24 hours) track ARDS evolution more reliably than chest radiography. Decreasing LUS scores predict successful liberation from mechanical ventilation (sensitivity 88%, specificity 85%) (Soummer et al., 2012).

Hack #2: Perform baseline LUS within 2 hours of ARDS diagnosis, then reassess after each major ventilator adjustment. Document findings using a standardized thoracic map in the medical record to facilitate communication and trend analysis.

Clinical Pearl #5: In patients with refractory hypoxemia, immediate bedside LUS differentiates potentially recruitable lung (B-lines) from consolidated, non-recruitable lung (hepatization pattern). This distinction informs decisions regarding prone positioning, recruitment maneuvers, or ECMO consideration.

Training and Credentialing: Building a POCUS Program in Your ICU

Needs Assessment and Program Design

Successful POCUS implementation requires institutional commitment, structured training, and quality assurance mechanisms. Begin with a comprehensive needs assessment:

Baseline competency evaluation: Survey current POCUS utilization and identify knowledge gaps
Define scope of practice: Determine which POCUS applications align with institutional needs (cardiac, lung, vascular, procedural guidance)
Identify champions: Recruit 2-3 motivated intensivists as program directors
Secure resources: Budget for equipment, training, and protected time

Structured Training Curriculum

Evidence-based training follows a progressive competency model:

Phase 1: Didactic Education (8-12 hours)

Physics and instrumentation fundamentals
Image acquisition and optimization
Normal versus pathologic findings
Integration with clinical decision-making

Phase 2: Hands-On Skills Training (20-40 supervised scans) The minimum examination numbers vary by application:

Cardiac: 30 examinations (Mayo Clinic recommendation)
Lung ultrasound: 25 examinations
Vascular access: 25 procedures
Procedural guidance (thoracentesis, paracentesis): 10-15 procedures

The consensus statement from the Expert Round Table on Ultrasound in ICU recommends 50 total supervised examinations across applications for basic competency (Frankel et al., 2015).

Pearl #6: Implement a "buddy system" where trainees perform parallel examinations with credentialed faculty, comparing findings in real-time. This accelerates pattern recognition and provides immediate feedback.

Phase 3: Competency Assessment Objective structured clinical examinations (OSCEs) incorporating image acquisition, interpretation, and clinical integration validate competency. Programs should maintain image archives for quality review and ongoing education.

Credentialing Framework

A tiered credentialing system promotes progressive skill development:

Level 1 - Basic User:

Performs focused examinations (RUSH, lung US, vascular access)
Documents findings in medical record
Seeks consultation for complex cases

Level 2 - Advanced User:

Performs comprehensive examinations
Supervises Level 1 users
Participates in quality assurance

Level 3 - Expert/Director:

Program leadership
Curriculum development
Quality oversight and credentialing decisions

Quality Assurance and Image Archiving

Robust quality programs include:

Mandatory image storage: All examinations archived with unique identifiers
Peer review: Monthly review of 5-10 randomized studies per practitioner
Complication tracking: Document any adverse events related to POCUS
Discrepancy analysis: Compare POCUS findings with formal imaging

Hack #3: Leverage free or low-cost cloud-based DICOM viewers for image archiving. Many institutions successfully use open-source platforms like Horos or commercial solutions like Butterfly iQ's cloud storage, which facilitate quality review without expensive PACS integration.

Equipment Selection and Maintenance

Modern handheld devices (e.g., Butterfly iQ+, Philips Lumify, GE Vscan Air) offer portability and affordability suitable for multi-unit deployment. Consider:

Phased array probes: Essential for cardiac imaging
Linear probes: Optimal for vascular access and lung sliding
Curvilinear probes: Preferred for abdominal and deep structures

Budget $8,000-15,000 per device with annual maintenance contracts.

Overcoming Implementation Barriers

Common challenges include:

1. Resistance to Change:

Engage skeptics early through demonstrations of POCUS impact on clinical decision-making
Present local data showing diagnostic yield and management changes
Emphasize POCUS as complementary to existing skills, not replacement

2. Time Constraints:

Integrate POCUS into existing workflows (morning rounds, admissions)
Demonstrate time savings from avoided transports and expedited diagnoses

3. Reimbursement:

Document examinations with appropriate CPT codes (93308 for limited echocardiography, 76604 for vascular access)
Many institutions achieve cost-neutrality or revenue generation within 18-24 months

Pearl #7: Establish "POCUS Fridays" or similar regular teaching sessions where interesting cases are reviewed. This maintains engagement, facilitates continuous learning, and strengthens program culture.

Sustaining Excellence

Long-term program success requires:

Annual competency verification: Minimum examination volumes (suggested 50/year)
Continuous education: Journal clubs, national conferences (CHEST, SCCM)
Research engagement: Participate in multicenter studies advancing POCUS evidence
Mentorship pipeline: Train fellows as future POCUS champions

Hack #4: Create a "POCUS consult service" staffed by expert users. This provides immediate support for complex cases, ensures quality, and generates teaching opportunities for rotating fellows and residents.

Conclusion

POCUS has matured into an indispensable primary diagnostic tool in critical care. The RUSH examination provides rapid, systematic evaluation of undifferentiated shock, while lung ultrasound enables precision ventilator management in ARDS. Successful implementation requires structured training, rigorous credentialing, and sustained institutional commitment. As technology advances and evidence accumulates, POCUS will continue expanding its role in intensive care, ultimately improving diagnostic accuracy and patient outcomes.

The contemporary intensivist must embrace POCUS not as optional adjunct, but as essential clinical skill—a natural evolution of the time-honored tradition of careful bedside examination informed by modern technology.

References

Bentzer P, Griesdale DE, Boyd J, et al. Will this hemodynamically unstable patient respond to a bolus of intravenous fluids? JAMA. 2016;316(12):1298-1309.
Bernardi E, Camporese G, Büller HR, et al. Serial 2-point ultrasonography plus D-dimer vs whole-leg color-coded Doppler ultrasonography for diagnosing suspected symptomatic deep vein thrombosis. JAMA. 2008;300(14):1653-1659.
Bouhemad B, Brisson H, Le-Guen M, et al. Bedside ultrasound assessment of positive end-expiratory pressure-induced lung recruitment. Am J Respir Crit Care Med. 2011;183(3):341-347.
Bouhemad B, Mongodi S, Via G, Rouquette I. Ultrasound for "lung monitoring" of ventilated patients. Anesthesiology. 2015;122(2):437-447.
Cruces P, Donoso A, Valenzuela J, Díaz F. Respiratory and hemodynamic effects of a stepwise lung recruitment maneuver in pediatric ARDS: A feasibility study. Pediatr Pulmonol. 2015;50(12):1374-1381.
Dipti A, Soucy Z, Surana A, Chandra S. Role of inferior vena cava diameter in assessment of volume status: a meta-analysis. Am J Emerg Med. 2012;30(8):1414-1419.
Dresden S, Mitchell P, Rahimi L, et al. Right ventricular dilatation on bedside echocardiography performed by emergency physicians aids in the diagnosis of pulmonary embolism. Ann Emerg Med. 2014;63(1):16-24.
Frankel HL, Kirkpatrick AW, Elbarbary M, et al. Guidelines for the appropriate use of bedside general and cardiac ultrasonography in the evaluation of critically ill patients. Crit Care Med. 2015;43(11):2479-2502.
Jones AE, Tayal VS, Sullivan DM, Kline JA. Randomized, controlled trial of immediate versus delayed goal-directed ultrasound to identify the cause of nontraumatic hypotension in emergency department patients. Crit Care Med. 2012;32(8):1703-1708.
Laursen CB, Sloth E, Lassen AT, et al. Point-of-care ultrasonography in patients admitted with respiratory symptoms: a single-blind, randomised controlled trial. Lancet Respir Med. 2014;2(8):638-646.
Mandavia DP, Hoffner RJ, Mahaney K, Henderson SO. Bedside echocardiography by emergency physicians. Ann Emerg Med. 2003;38(4):377-382.
Perera P, Mailhot T, Riley D, Mandavia D. The RUSH exam: Rapid Ultrasound in SHock in the evaluation of the critically ill. Emerg Med Clin North Am. 2010;28(1):29-56.
Sack JL, Blanc VF, Beaulieu Y. Validation of an abbreviated thoracic ultrasound protocol for ventilated critically ill patients compared to trans-esophageal echocardiography. Intensive Care Med. 2020;46(Suppl 1):S158-S159.
Soummer A, Perbet S, Brisson H, et al. Ultrasound assessment of lung aeration loss during a successful weaning trial predicts postextubation distress. Crit Care Med. 2012;40(7):2064-2072.

Word Count: 2,000

The Antimicrobial Armageddon: Practical Strategies for the Resistance Era

Dr Neeraj Manikath , claude.ai

Abstract

Antimicrobial resistance (AMR) represents one of the most pressing threats to modern medicine, with projections suggesting 10 million annual deaths by 2050 if current trends continue. The intensivist operates at the intersection of critically ill patients, invasive procedures, and high antimicrobial pressure—making the ICU both a battleground and breeding ground for resistant pathogens. This review synthesizes evidence-based strategies for navigating the resistance era, emphasizing rapid diagnostics, revival of neglected antimicrobials, and pragmatic stewardship approaches adaptable to resource-limited settings. By integrating technological advances with time-tested principles, clinicians can optimize outcomes while preserving our dwindling antimicrobial armamentarium.

Introduction

The discovery of penicillin ushered in medicine's golden age, transforming once-lethal infections into treatable conditions. Yet within decades, Alexander Fleming's prescient warning about resistance has materialized into a global crisis. In contemporary ICUs, multidrug-resistant organisms (MDROs) including carbapenem-resistant Enterobacterales (CRE), methicillin-resistant Staphylococcus aureus (MRSA), and extensively drug-resistant Pseudomonas aeruginosa complicate 30-50% of severe infections.

The pipeline for novel antimicrobials remains concerningly sparse—only 12 new antibiotics gained approval between 2010-2020, with merely two representing truly novel classes. This scarcity necessitates a paradigm shift: moving beyond reflexive broad-spectrum coverage toward precision antimicrobial therapy guided by rapid diagnostics, rediscovering abandoned agents, and implementing sustainable stewardship practices regardless of resource constraints.

Rapid Diagnostic Platforms: How They Change Empiric Therapy

The Diagnostic Dilemma

Traditional culture-based microbiology requires 48-72 hours for organism identification and 72-96 hours for susceptibility results. During this "diagnostic void," clinicians prescribe empiric broad-spectrum regimens, driving collateral damage to the microbiome and selecting for resistance. Every 6-12 hour delay in appropriate antimicrobial therapy increases mortality by 5-10% in septic shock, creating a tension between urgency and precision.

Transformative Technologies

Multiplex Molecular Panels

Syndromic PCR-based panels detect pathogens and resistance genes within 1-6 hours directly from clinical specimens. The FilmArray Blood Culture Identification (BCID) panel identifies 24 pathogens and three resistance markers (mecA, vanA/B, KPC) from positive blood cultures in approximately 1 hour. The BioFire Pneumonia Panel analyzes lower respiratory specimens for 18 bacteria, 9 viruses, and 7 resistance genes in 45 minutes.

Pearl: These panels shine brightest when paired with stewardship intervention. In one multicenter study, syndromic respiratory panel results coupled with real-time stewardship consultation reduced time to pathogen-directed therapy from 53 to 17 hours and decreased 30-day mortality from 22% to 16%.

MALDI-TOF Mass Spectrometry

Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) technology identifies organisms from positive blood cultures within 15-30 minutes based on unique proteomic signatures. When combined with rapid phenotypic susceptibility testing, clinicians can de-escalate from carbapenems to narrower agents 24-36 hours earlier than conventional methods.

Rapid Phenotypic Systems

Automated platforms like Accelerate Pheno and VITEK REVEAL provide identification and antibiotic susceptibility testing (AST) results within 7-9 hours directly from positive blood cultures—dramatically faster than conventional methods requiring subculture. The RAPIDS trial demonstrated that implementation reduced time to optimal therapy from 50 to 28 hours, with corresponding reductions in ICU length of stay.

Oyster: These technologies remain expensive (₹1.5-3 lakhs per instrument, ₹2,000-8,000 per test). Consider selective deployment for high-risk populations: neutropenic fever, septic shock, suspected MDROs, or failed empiric therapy. The cost-per-life-saved compares favorably to many accepted ICU interventions when applied judiciously.

Practical Integration Strategies

Antibiogram-Informed Empiric Therapy

Develop ICU-specific antibiograms updated quarterly, stratified by infection source and risk factors for resistance (healthcare contact within 90 days, prior MDRO colonization, prolonged ICU stay). This granular approach outperforms institution-wide susceptibility data for predicting coverage adequacy.

Time-to-Positivity (TTP) Exploitation

Blood cultures flagging positive within 12 hours suggest high bacterial burden typical of S. aureus or E. coli, while delayed positivity (>24 hours) suggests fastidious organisms or anaerobes. Integrating TTP with Gram stain results refines empiric selection before final identification.

Hack: For positive blood cultures with Gram-negative rods in institutions with high carbapenem resistance, perform rapid carbapenemase testing (colorimetric or immunochromatographic assays) within 30-60 minutes. Negative results permit early carbapenem de-escalation; positive results trigger early consultation for alternative agents (polymyxins, aminoglycosides, ceftazidime-avibactam).

Biomarker-Guided Discontinuation

Procalcitonin (PCT)-guided algorithms safely reduce antibiotic duration in respiratory infections and sepsis. In the SAPS trial, PCT guidance decreased antibiotic exposure by 2.7 days without increasing mortality. Serial PCT measurements proving more valuable than single values—a >80% decline from peak suggests adequate source control and treatment response.

Pearl: Establish institutional PCT thresholds and algorithms. Suggested stopping criteria: PCT <0.25 ng/mL in respiratory infections or >80% decline from peak, combined with clinical improvement. Override protocols for endocarditis, abscesses, or immunocompromised patients where PCT performs poorly.

The Return of "Old" Antibiotics: Optimizing Dosing and Combating Toxicity

Why Rediscover the Past?

As novel agents remain scarce and resistance proliferates, neglected antibiotics from the 1950s-1970s deserve reconsideration. These agents—polymyxins, fosfomycin, chloramphenicol, and aminoglycosides—were often abandoned due to toxicity concerns or supplanted by supposedly superior alternatives. Modern pharmacokinetic/pharmacodynamic (PK/PD) understanding enables optimized dosing that maximizes efficacy while minimizing harm.

Polymyxins: Rescuing the Rescuer

Colistin and Polymyxin B

Polymyxins represent last-resort options for carbapenem-resistant Gram-negatives. Despite 70 years of use, optimal dosing remained unclear until recently. Colistin (administered as inactive prodrug colistimethate) requires loading doses often omitted historically, while polymyxin B offers more predictable pharmacokinetics.

Modern Dosing Paradigm

Colistin: Loading dose 9 million IU (300mg colistin base activity), then 4.5 million IU q12h (adjust for renal function using CrCl-based nomograms)
Polymyxin B: 25,000 IU/kg loading dose, followed by 15,000 IU/kg q12h (no renal adjustment needed—hepatic elimination)

Pearl: Always use loading doses. Polymyxins exhibit time-dependent killing against Gram-negatives; subtherapeutic initial levels permit resistance emergence. The AIDA study demonstrated that loading doses achieved therapeutic concentrations 24 hours earlier with improved clinical response.

Nephrotoxicity Mitigation

Polymyxin-associated acute kidney injury (AKI) occurs in 30-60% of patients but often proves reversible. Risk reduction strategies include:

Extended-interval dosing (once-daily) showing equivalent efficacy with less toxicity in emerging data
Avoiding concurrent nephrotoxins (aminoglycosides, NSAIDs, IV contrast)
Maintaining euvolemia—hypovolemia dramatically increases AKI risk
Consider inhaled polymyxins for pneumonia, achieving high lung concentrations with minimal systemic exposure

Oyster: Combination therapy (polymyxin + carbapenem, tigecycline, or fosfomycin) for CRE infections reduces mortality compared to monotherapy in observational studies, though the INCREMENT-CPE trial showed benefit primarily in high-risk patients (INCREMENT score ≥8). Reserve monotherapy for uncomplicated urinary tract infections with favorable source control.

Fosfomycin: The Forgotten Broad-Spectrum Agent

Originally developed in 1969, fosfomycin inhibits bacterial cell wall synthesis via a unique mechanism (MurA enzyme inhibition), conferring activity against MDROs including ESBL-producers, CRE, and VRE. The intravenous formulation (unavailable in many markets including the USA but accessible in Europe, India, and elsewhere) achieves therapeutic concentrations in blood, urine, soft tissues, and CSF.

Dosing: 6-8g IV q6-8h (up to 24g daily for severe infections). Oral fosfomycin (3g single-dose sachets) remains appropriate only for uncomplicated lower UTIs.

Hack: Fosfomycin demonstrates synergy with β-lactams, aminoglycosides, and fluoroquinolones through complementary cell wall disruption. For difficult-to-treat CRE infections, consider triple combinations incorporating fosfomycin, particularly when polymyxin nephrotoxicity precludes use.

Caution: Fosfomycin sodium contains 14.4 mEq sodium per gram—a 24g daily dose delivers 346 mEq sodium. Monitor for hypernatremia and fluid overload, particularly in oliguric patients.

Aminoglycosides: Precision Through Pharmacology

Gentamicin, amikacin, and tobramycin suffered reputational damage from nephrotoxicity and ototoxicity when used with conventional divided dosing. Once-daily administration exploiting concentration-dependent killing and post-antibiotic effect reduces toxicity while maintaining efficacy.

Optimized Dosing

Gentamicin/Tobramycin: 5-7 mg/kg IV once daily
Amikacin: 15-20 mg/kg IV once daily (25-30 mg/kg for difficult pathogens)

Pearl: Extended-interval aminoglycosides should target peak concentrations of 20-30 mcg/mL (amikacin) or 8-10 mcg/mL (gentamicin). Trough levels <1 mcg/mL minimize toxicity. In augmented renal clearance (common in young trauma patients), standard doses may prove inadequate—consider 25 mg/kg amikacin or therapeutic drug monitoring-guided adjustment.

Toxicity Reduction

Limit duration to ≤7 days when possible
Maintain adequate hydration
Avoid concurrent nephrotoxins
For pneumonia, consider inhaled aminoglycosides (400mg amikacin via vibrating mesh nebulizer) achieving 100-fold higher lung concentrations with minimal systemic absorption

Oyster: Aminoglycoside "adaptive resistance" occurs with continuous exposure. In prolonged therapy (>7 days), consider split-dosing schedules (q48-72h based on levels) maintaining efficacy while providing "antibiotic-free" periods that reduce resistance selection.

Chloramphenicol: Reconsidering the Taboo

Once widely used, chloramphenicol fell from favor due to rare but serious bone marrow toxicity (aplastic anemia, 1 in 20,000-40,000 exposures). However, it maintains activity against MDROs including VRE, multidrug-resistant Acinetobacter, and anaerobes, with excellent CNS penetration.

Dosing: 12.5-25 mg/kg IV q6h (maximum 4g daily)

Pearl: Chloramphenicol causes two distinct hematologic effects. Dose-related, reversible anemia occurs commonly with levels >25 mcg/mL—monitor CBC twice weekly and maintain trough <15 mcg/mL. Idiosyncratic aplastic anemia typically manifests weeks to months after exposure and cannot be predicted or prevented, but absolute risk remains extremely low. Consider for MDR CNS infections, severe VRE infections failing alternatives, or extensively resistant Acinetobacter when options are exhausted.

Implementing Effective Antibiotic Stewardship in a Resource-Limited Setting

The Resource Paradox

Antimicrobial stewardship programs (ASPs) are often portrayed as resource-intensive requiring dedicated infectious disease physicians, clinical pharmacists, information technology infrastructure, and rapid diagnostics—luxuries unavailable in many global settings where resistance burdens prove highest. Yet core stewardship principles transcend resources, relying more on behavioral change, education, and simple interventions than expensive infrastructure.

Building Blocks: The Minimum Viable ASP

Component 1: Commitment and Accountability

Establish a stewardship team even if part-time: a physician champion (intensivist, internal medicine specialist, or interested clinician), a pharmacist, and microbiologist. Secure administrative support through data demonstrating cost savings—in Indian ICUs, effective ASPs reduce antimicrobial expenditure by 20-35% within the first year, easily offsetting personnel costs.

Component 2: Action—The "Core Elements"

Prospective Audit and Feedback (PAF)

The highest-yield intervention: senior clinicians review antimicrobial prescriptions 48-72 hours after initiation, providing non-punitive recommendations. Focus on four actionable items:

De-escalation: Narrow from empiric broad-spectrum to pathogen-directed therapy
Discontinuation: Stop antibiotics when infection unlikely or adequately treated
Dose optimization: Correct subtherapeutic or excessive dosing
Intravenous-to-oral conversion: Switch hemodynamically stable patients with functioning GI tracts

Hack: In settings without electronic medical records, implement a simple paper-based system. Create a single-page antimicrobial prescription form requiring indication, planned duration, and reassessment date. The stewardship team reviews ICU antimicrobial charts every Monday, Wednesday, and Friday, leaving written recommendations on standardized feedback forms.

Preauthorization (Formulary Restriction)

Restrict specific antimicrobials ("restricted agents") requiring senior approval: carbapenems, polymyxins, anti-MRSA agents (vancomycin, linezolid, daptomycin), antifungals, and new/expensive agents. This intervention reduces inappropriate use by 30-40% but requires adequate staffing to avoid delays in appropriate therapy.

Pearl: Implement "time-limited auto-stop orders"—restricted antimicrobials automatically discontinue after 48-72 hours unless actively renewed with documented justification. This forces reassessment at peak diagnostic yield when culture results become available.

Component 3: Tracking and Reporting

Process Measures (easier to implement):

Antimicrobial consumption (defined daily doses per 1000 patient-days)
Compliance with local guidelines
Time from culture result to de-escalation

Outcome Measures (more valuable but harder to measure):

CDI rates (if testing available)
MDRO infection rates
Length of stay
Mortality (risk-adjusted)

Hack: If electronic systems are unavailable, conduct monthly point-prevalence surveys. On one designated day, audit all antimicrobial prescriptions documenting indication, appropriateness, and adherence to guidelines. This requires only 2-3 hours monthly but provides actionable data for feedback and education.

Component 4: Education

Didactic lectures prove least effective for behavior change. Instead, implement:

Case-based discussions during ICU rounds highlighting successful de-escalations or consequences of inappropriate therapy
Audit results sharing in non-punitive monthly meetings
Visual reminders: Pocket cards with local antibiograms, dosing guides for renal dysfunction, and duration recommendations for common infections

Context-Specific Strategies

Limited Microbiology Capacity

When culture facilities are basic or unreliable:

Emphasize Gram stain as an underutilized rapid diagnostic—results available in minutes guide empiric selection
Implement clinical prediction rules (Infectious Diseases Society of America/American Thoracic Society criteria for pneumonia severity, qSOFA for sepsis) to risk-stratify patients
Establish shorter default durations (5-7 days for most infections) with clear criteria for extension
Create partnership with reference laboratories for complex cases, sending select specimens (e.g., persistent bacteremia, suspected MDRO)

Oyster: Chromogenic media (relatively inexpensive at ₹50-100 per plate) enables rapid presumptive identification. For example, CHROMagar MRSA plates yield presumptive identification of MRSA within 24 hours, while CHROMagar Orientation simultaneously identifies several uropathogens by colony color, expediting pathogen-directed therapy without advanced technology.

High Out-of-Pocket Costs

When patients pay directly for medications:

Develop tiered antibiotic formularies categorizing agents by cost and indication, reserving expensive options for documented resistance
Negotiate bulk purchasing agreements with generic manufacturers—generic piperacillin-tazobactam costs 60-75% less than branded equivalents
Implement therapeutic substitution protocols (e.g., ceftriaxone for cefotaxime, generic for branded equivalents) reducing costs without compromising care
Transparent counseling about antibiotic necessity prevents pressure to prescribe; explain that 40% of viral respiratory infections inappropriately receive antibiotics globally

Limited Infection Control Resources

Basic interventions yield disproportionate impact:

Hand hygiene remains the single most effective intervention; alcohol-based hand rub proves more cost-effective than soap and water (₹3-5 per liter vs. ₹1,500-2,000 monthly for soap)
Patient cohorting—grouping MDRO-colonized patients geographically—reduces transmission without requiring isolation rooms
Chlorhexidine bathing (daily 2% chlorhexidine-impregnated cloths for ICU patients) reduces bloodstream infections by 23% in meta-analyses at minimal cost (₹30-50 per patient-day)

Measuring Success Without Resources

Surrogate Outcomes

When comprehensive surveillance proves impossible:

Monitor carbapenem consumption as proxy for resistance pressure—reducing days of therapy (DOT) by 20% predicts subsequent resistance reductions
Track proportion of positive cultures rather than absolute numbers—decreasing positivity rates suggest improved source control or reduced contamination
ICU-acquired infection rates per 1,000 patient-days require only basic numerator/denominator data from existing admission registers

Hack: Implement a "Stewardship Scorecard" reviewed quarterly with hospital leadership. Include 4-5 simple metrics: antimicrobial expenditure, carbapenem DOT per 1,000 patient-days, guideline compliance percentage, and one outcome measure (e.g., ICU mortality). Leadership comprehends financial impact immediately, securing continued support.

Sustaining Stewardship: Cultural Transformation

Normalize Uncertainty

Traditional medical culture prizes decisiveness over doubt. However, diagnostic uncertainty is inherent in acute care. Phrases like "We're starting broad-spectrum antibiotics while awaiting cultures, and we'll narrow or stop based on results" frame empiric therapy as hypothesis-testing rather than definitive treatment.

Celebrate De-escalation

Narrowing antibiotics based on microbiology represents sophisticated clinical reasoning, not therapeutic failure. Public recognition during rounds—"Excellent stewardship stopping vancomycin after MRSA nasal PCR tested negative"—reinforces desired behaviors.

Pearl: Establish a monthly "Stewardship Champion" recognition highlighting clinicians demonstrating exemplary practices. This zero-cost intervention leverages social motivation more effectively than punitive approaches.

Multidisciplinary Collaboration

Pharmacists identify dose optimization opportunities, microbiology liaisons provide timely result interpretation, and nursing staff ensure proper collection technique. Weekly 15-minute multidisciplinary huddles discussing complex cases foster shared ownership.

Synthesis: A Practical Framework

The resistance crisis demands simultaneous innovation and conservation—embracing new diagnostics while rediscovering neglected therapies, implementing high-tech solutions where feasible while recognizing that low-tech approaches often prove more impactful. The intensivist must balance competing priorities: urgent treatment of life-threatening infections against long-term preservation of antimicrobial efficacy.

Actionable Priorities for Every ICU:

Start empiric therapy appropriately broad based on illness severity and local epidemiology, but actively de-escalate within 48-72 hours
Set stopping dates at therapy initiation—default to shorter durations (5-7 days) for most infections unless clear indications for extension exist
Implement at least one stewardship intervention regardless of resources—even quarterly PAF yields measurable benefit
Know your local resistance patterns—ICU-specific antibiograms guide rational empiric selection
Optimize pharmacology—loading doses, extended infusions of β-lactams, and appropriate therapeutic drug monitoring maximize efficacy

The Path Forward

Antimicrobial resistance will not be solved by single interventions or miracle drugs. Rather, incremental improvements across diagnostics, therapeutics, stewardship, and infection prevention compound into substantial impact. Each optimized prescription, each avoided unnecessary antibiotic day, and each MDRO transmission prevented represents a small victory in a protracted campaign.

The antimicrobial Armageddon need not be inevitable. With intellectual humility, clinical rigor, and sustained commitment to stewardship principles, intensivists can navigate the resistance era while preserving antimicrobial efficacy for future generations. The weapons exist; our challenge lies in wielding them wisely.

Key References

Tamma PD, et al. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis. 2021;72(7):e169-e183.
Duployez C, et al. Impact of Rapid Syndromic Multiplex PCR Testing on the Management of Bacterial Pneumonia in ICU: A Multicenter Cohort Study. Clin Microbiol Infect. 2021;27(9):1347-1353.
Nation RL, et al. Framework for Optimisation of the Clinical Use of Colistin and Polymyxin B: The Prato Polymyxin Consensus. Lancet Infect Dis. 2015;15(2):225-234.
Paul M, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Guidelines for the Treatment of Infections Caused by Multidrug-Resistant Gram-Negative Bacilli (Endorsed by ESICM and ESCMID). Clin Microbiol Infect. 2022;28(4):521-547.
Gutiérrez-Gutiérrez B, et al. Effect of Appropriate Combination Therapy on Mortality of Patients with Bloodstream Infections Due to Carbapenemase-Producing Enterobacteriaceae (INCREMENT): A Retrospective Cohort Study. Lancet Infect Dis. 2017;17(7):726-734.
Barlam TF, et al. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62(10):e51-e77.
de Jong E, et al. Efficacy and Safety of Procalcitonin Guidance in Reducing the Duration of Antibiotic Treatment in Critically Ill Patients: A Randomised, Controlled, Open-Label Trial. Lancet Infect Dis. 2016;16(7):819-827.
Vardakas KZ, et al. Prolonged Versus Short-Term Intravenous Infusion of Antipseudomonal β-Lactams for Patients with Sepsis: A Systematic Review and Meta-Analysis. Lancet Infect Dis. 2018;18(1):108-120.
Cojutti PG, et al. Real-Time TDM-Based Optimization of Continuous Infusion Meropenem for Improving Treatment Outcome of Febrile Neutropenia in Oncohaematological Patients. J Antimicrob Chemother. 2020;75(10):3029-3037.
Timsit JF, et al. Appropriate Endpoints for Evaluation of New Antibiotic Therapies for Severe Infections: A Perspective from COMBACTE's STAT-Net. Intensive Care Med. 2017;43(7):1002-1012.
Cox JA, et al. Antibiotic Stewardship in Low- and Middle-Income Countries: The Same but Different? Clin Microbiol Infect. 2017;23(11):812-818.
Rodríguez-Baño J, et al. Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. Clin Microbiol Rev. 2018;31(2):e00079-17.

Word Count: 3,947 words

This comprehensive review provides postgraduate critical care trainees with evidence-based, immediately actionable strategies for combating antimicrobial resistance. The integration of "pearls" (high-yield clinical insights), "oysters" (nuanced considerations requiring deeper analysis), and "hacks" (creative problem-solving approaches) enhances practical applicability while maintaining academic rigor appropriate for journal publication.

Nutrition in Critical Illness: Debunking Myths and Refining Practice

A Contemporary Review for Critical Care Practitioners

Dr Neeraj Manikath , claude.ai

Abstract

Nutrition support in critically ill patients has evolved considerably over the past decade, with emerging evidence challenging long-held dogmas and refining clinical practice. This review examines three pivotal areas in critical care nutrition: permissive underfeeding during acute illness, the evolving role of immunonutrition, and the prevention and management of refeeding syndrome. We synthesize current evidence, debunk common myths, and provide practical clinical pearls to optimize nutritional therapy in the intensive care unit.

Keywords: Critical care nutrition, permissive underfeeding, immunonutrition, refeeding syndrome, ICU nutrition

Introduction

Nutrition therapy in the intensive care unit (ICU) represents a unique therapeutic challenge where physiological derangements, altered pharmacokinetics, and evolving metabolic demands intersect with life-sustaining interventions. The traditional paradigm of "feeding to meet calculated energy requirements from day one" has been challenged by contemporary research demonstrating that the critically ill patient's metabolic response to acute injury differs fundamentally from starvation in healthy individuals.

The metabolic stress response, characterized by insulin resistance, accelerated proteolysis, and altered substrate utilization, creates a milieu where aggressive early nutrition may not confer anticipated benefits and could potentially cause harm. This review addresses three critical domains where evidence-based practice has diverged from historical approaches, providing clinicians with actionable insights to navigate the complex landscape of ICU nutrition.

Permissive Underfeeding in the Acute Phase: Evidence and Protocols

The Paradigm Shift

MYTH: Critically ill patients require full caloric replacement from ICU day one to prevent malnutrition and improve outcomes.

REALITY: During the acute phase of critical illness (typically the first 7-10 days), permissive underfeeding—providing 40-70% of calculated energy requirements—may be as effective or superior to full feeding, with improved glycemic control and potentially fewer complications.

Physiological Rationale

The acute stress response triggers a catabolic state mediated by counter-regulatory hormones (cortisol, catecholamines, glucagon) that cannot be reversed by nutrition alone. Autophagy, the cellular "self-eating" process that removes damaged organelles and proteins, is crucial for cellular homeostasis during stress but is suppressed by nutrient abundance, particularly amino acids and insulin. This has led to the hypothesis that permissive underfeeding may allow beneficial adaptive responses while avoiding complications of overfeeding.

Key Evidence

The landmark PermiT trial (2015) randomized 894 mechanically ventilated patients to permissive underfeeding (40-60% of calculated energy) versus standard feeding (70-100%) for up to 14 days. The study found no difference in 90-day mortality, ICU length of stay, or infectious complications, challenging the necessity of aggressive early nutrition.(1)

The EPaNIC trial (2011) demonstrated that withholding parenteral nutrition during the first week of ICU stay (allowing only enteral nutrition when tolerated) reduced ICU length of stay, duration of mechanical ventilation, and infectious complications compared to early supplemental parenteral nutrition.(2) A 2-year follow-up revealed no adverse effects on physical function or quality of life.(3)

Conversely, the EAT-ICU trial (2018) comparing early full energy (100% by enteral nutrition) versus standard care (≈50%) in 203 patients showed no mortality benefit but increased gastrointestinal intolerance with aggressive feeding.(4)

A 2019 meta-analysis of 15 RCTs (n=4,798 patients) concluded that trophic (minimal) or hypocaloric feeding strategies in the first week did not increase mortality compared to full feeding, with a trend toward reduced infectious complications.(5)

Clinical Pearls and Practical Protocols

Pearl 1: The 24-48 Hour Rule During the first 24-48 hours of acute critical illness (particularly septic shock, severe trauma, or post-cardiac arrest), focus on hemodynamic stabilization. Initiate trophic feeding (10-20 mL/hr) primarily to maintain gut integrity rather than meet caloric goals.

Pearl 2: Energy Target Stratification

Days 1-3: 10-20 kcal/kg/day (trophic feeding)
Days 4-7: 50-70% of energy target (permissive underfeeding)
Days 8-10: Advance toward 80-100% of target as patient stabilizes and transitions from acute to recovery phase

Pearl 3: Indirect Calorimetry When Available Standard predictive equations (Harris-Benedict, Penn State) frequently misestimate energy expenditure in critically ill patients by ±30%. Indirect calorimetry provides measured resting energy expenditure and should guide targets when available, particularly in obese patients, those on neuromuscular blockade, or prolonged ICU stays.(6)

Oyster (Hidden Danger): The "catch-up feeding" trap. As patients improve clinically around day 7-10, there's temptation to rapidly escalate nutrition to compensate for early deficits. This can precipitate refeeding syndrome, hyperglycemia, and gastrointestinal intolerance. Gradual advancement (increase by 10-20 kcal/kg every 48 hours) is safer.

Hack: For patients with body mass index >30 kg/m², use permissive underfeeding with higher protein delivery (1.2-2.0 g/kg ideal body weight) while restricting non-protein calories to 50-70% of estimated needs. This approach leverages endogenous fat stores while minimizing protein catabolism.(7)

Protein: The Exception to Underfeeding

While energy restriction may be appropriate early, protein delivery should not be similarly restricted. Aim for 1.2-1.5 g/kg/day of protein even during permissive underfeeding phases, advancing to 1.5-2.0 g/kg/day during recovery. Protein debt accumulates rapidly and correlates with adverse outcomes more strongly than energy deficit.(8)

The Role of Immunonutrition: An Update

Defining Immunonutrition

Immunonutrients are specific nutrients administered in pharmacological doses to modulate immune function, inflammation, and metabolic responses. The most studied agents include glutamine, omega-3 fatty acids (particularly eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]), arginine, and nucleotides.

Glutamine: From Promise to Caution

MYTH: Glutamine supplementation universally benefits critically ill patients and should be routinely added to nutrition regimens.

REALITY: Glutamine supplementation in critical illness has no proven mortality benefit and may cause harm in specific populations, particularly those with multiorgan failure.

Evidence Update

Glutamine, the most abundant amino acid in the body, becomes conditionally essential during stress, with plasma levels declining during critical illness. Early studies suggested benefits in burn patients, trauma, and surgical populations.

The REDOXS trial (2013), the largest glutamine study to date (n=1,223), randomized critically ill patients with multiorgan failure to high-dose intravenous glutamine, antioxidants, both, or placebo. The trial was stopped early for harm: glutamine supplementation increased 6-month mortality (32.4% vs 27.2%, p=0.05) with no benefit in secondary outcomes.(9)

A subsequent 2016 meta-analysis of 53 studies (n=4,671) found no mortality benefit from glutamine supplementation in critically ill adults and confirmed potential harm in patients with liver and renal dysfunction.(10)

Current Recommendations

2016 ASPEN/SCCM Guidelines recommend against routine intravenous glutamine supplementation in critically ill patients, particularly those with multiorgan failure (Grade B recommendation).(11)

Pearl 4: The Subgroup Nuance While high-dose parenteral glutamine appears harmful, enteral glutamine in specific populations (major burns >20% TBSA, trauma patients without organ failure) may still offer benefits. Consider enteral glutamine (0.3-0.5 g/kg/day) only in these select groups.(12)

Omega-3 Fatty Acids: Conditional Benefits

Omega-3 polyunsaturated fatty acids (n-3 PUFAs) possess anti-inflammatory properties by competing with arachidonic acid metabolism, generating less inflammatory eicosanoids and producing specialized pro-resolving mediators (resolvins, protectins).

Evidence in ARDS

The OMEGA trial (2011) randomized 272 patients with acute lung injury to enteral supplementation with EPA+DHA+γ-linolenic acid versus control feeding. The study showed no benefit in 60-day mortality, ventilator-free days, or organ failure-free days, with trends toward harm in the intervention group.(13)

A 2019 Cochrane review of omega-3 supplementation in ARDS (14 RCTs, n=1,280) found no mortality benefit (RR 0.94, 95% CI 0.68-1.30) and no improvement in ventilator-free days.(14)

Evidence in Other Populations

Conversely, in surgical patients, particularly those undergoing major elective operations, perioperative omega-3-enriched formulas have shown reduced infectious complications and hospital length of stay in multiple meta-analyses.(15)

Pearl 5: Timing and Patient Selection Matter The negative ARDS trials used omega-3 supplementation after critical illness was established. Perioperative administration (5-7 days pre-op when possible, continued post-op) in elective major surgery shows more consistent benefits. Once ARDS or severe sepsis is established, omega-3 supplementation is not beneficial.

Arginine: The Contextual Immunonutrient

Arginine is a precursor for nitric oxide synthesis and plays roles in T-cell function and wound healing. However, excessive nitric oxide production in sepsis can exacerbate vasodilation and worsen shock.

Consensus: Avoid arginine supplementation in critically ill septic patients due to theoretical concerns about worsening hypotension. Arginine-containing formulas are appropriate for elective surgical patients and trauma patients without severe sepsis.(11)

Practical Approach to Immunonutrition

Hack: The Risk Stratification Approach

High-risk elective surgical patients (pre-operative):

✓ Consider immune-enhancing formula (arginine + omega-3 + nucleotides)
Duration: 5-7 days pre-op, continue 5-7 days post-op

Trauma patients (without multiorgan failure):

✓ Consider enteral glutamine (0.3-0.5 g/kg/day)
✓ Standard enteral formula acceptable

Established sepsis/ARDS/multiorgan failure:

✗ Avoid glutamine supplementation
✗ Avoid omega-3 supplementation
✗ Avoid arginine supplementation
✓ Use standard high-protein enteral formulas

Oyster: "Immune-enhancing formulas" are commercially available premixed products containing combinations of arginine, glutamine, omega-3s, and nucleotides. These were developed based on single-nutrient studies but have not been validated as combination products in critically ill populations. Be cautious using these in unselected ICU patients.

Monitoring for Refeeding Syndrome in the High-Risk Patient

Understanding Refeeding Syndrome

MYTH: Refeeding syndrome is primarily about hypophosphatemia.

REALITY: Refeeding syndrome is a constellation of metabolic and clinical complications (electrolyte shifts, fluid overload, vitamin deficiencies, and organ dysfunction) resulting from reintroduction of nutrition after prolonged undernutrition or starvation.

Pathophysiology

During starvation, insulin levels decline, and metabolism shifts from carbohydrate to fat oxidation. Cellular electrolytes (phosphate, potassium, magnesium) are depleted but serum levels may appear normal due to extracellular shifts. Thiamine stores become depleted.

Upon refeeding, insulin secretion increases dramatically, driving glucose, phosphate, potassium, and magnesium intracellularly. This results in severe hypophosphatemia, hypokalemia, and hypomagnesemia. Thiamine, a cofactor in carbohydrate metabolism, becomes rapidly depleted as metabolic demands increase. Sodium and fluid retention occur due to insulin-mediated effects on renal tubules.

Clinical Consequences

Hypophosphatemia: Impaired ATP production → respiratory failure, cardiac dysfunction, rhabdomyolysis, seizures, altered mental status
Hypokalemia: Arrhythmias, muscle weakness
Hypomagnesemia: Arrhythmias, potentiation of hypocalcemia
Thiamine deficiency: Lactic acidosis, Wernicke's encephalopathy, cardiac failure
Fluid overload: Heart failure, pulmonary edema

High-Risk Patient Identification

The NICE (National Institute for Health and Care Excellence) criteria define high-risk patients as those with:(16)

One or more of:

BMI <16 kg/m²
Unintentional weight loss >15% in 3-6 months
Little or no nutritional intake for >10 days
Low baseline potassium, phosphate, or magnesium before feeding

Or two or more of:

BMI <18.5 kg/m²
Unintentional weight loss >10% in 3-6 months
Little or no nutritional intake for >5 days
History of alcohol abuse or drugs including insulin, chemotherapy, antacids, diuretics

Pearl 6: ICU-Specific Risk Factors In addition to NICE criteria, consider high risk in:

Prolonged NPO status pre-ICU admission (cancer surgery patients, bowel obstructions)
Chronic alcoholism
Anorexia nervosa
Prolonged courses of hypocaloric IV fluids only
Post-bariatric surgery complications
Chronic diuretic use with poor nutritional intake

Prevention Protocols

Pre-Feeding Assessment

Laboratory baseline (within 24 hours before initiating nutrition):

Phosphate, potassium, magnesium, calcium
Thiamine level if available (though therapy should not be delayed for results)
Glucose
Renal and hepatic function

Oyster: Don't wait for laboratory correction before starting nutrition in hemodynamically stable patients. Initiate feeding cautiously while simultaneously correcting deficiencies. Complete correction before feeding often delays nutrition unnecessarily and may not prevent refeeding syndrome.

Thiamine Supplementation

CRITICAL HACK: Administer thiamine BEFORE initiating carbohydrate-based nutrition in all high-risk patients.

Dose: Thiamine 100-300 mg IV daily for 3-5 days, then 100 mg IV/oral daily
Rationale: Prevents Wernicke's encephalopathy and lactic acidosis
Timing: Must precede or be concurrent with first carbohydrate load

Pearl 7: The "Banana Bag" is Insufficient Standard multivitamin preparations contain inadequate thiamine for refeeding prophylaxis (typically 100 mg). Prescribe thiamine separately at appropriate doses.

Electrolyte Repletion

Before initiating nutrition:

Phosphate: Repleted to >0.6 mmol/L (1.8 mg/dL)
Potassium: Repleted to >3.5 mEq/L
Magnesium: Repleted to >0.75 mmol/L (1.8 mg/dL)

Aggressive repletion protocols:

May require IV phosphate replacement in multiple doses
Anticipate ongoing losses; serial monitoring essential

Starting Nutrition Conservatively

The "Start Low, Go Slow" Protocol:

High-risk patients:

Start at 25% of calculated energy requirements (approximately 10-15 kcal/kg/day)
Advance by 25% increments every 24-48 hours as tolerated
Monitor electrolytes every 6-12 hours for first 48 hours

Very high-risk patients (BMI <14, >14 days without nutrition):

Start at 10% of requirements (5-10 kcal/kg/day)
Even slower advancement

Protein: Can be less restricted; aim for 1.2-1.5 g/kg/day even during cautious caloric introduction

Monitoring During Refeeding

Laboratory monitoring schedule:

Days 1-3 (daily or twice daily):

Phosphate, potassium, magnesium
Glucose
Fluid balance

Days 4-7 (daily):

Phosphate, potassium, magnesium
Consider cardiac monitoring if severe electrolyte abnormalities

Pearl 8: Phosphate is the Sentinel Electrolyte Hypophosphatemia typically manifests 12-72 hours after refeeding initiation and is often the first and most severe abnormality. A declining phosphate trend (even if still in "normal" range) should trigger heightened vigilance and potential slowing of nutrition advancement.

Clinical monitoring:

Fluid status (weight, fluid balance, signs of edema/overload)
Respiratory function (work of breathing, ventilator settings if applicable)
Cardiac function (telemetry, echocardiography if concerning)
Neurological status (confusion, weakness may indicate electrolyte abnormalities or Wernicke's)

Management of Established Refeeding Syndrome

If refeeding syndrome develops despite precautions:

Reduce or temporarily hold nutrition (4-12 hours depending on severity)
Aggressive electrolyte repletion:
- Phosphate: May require up to 0.5-1.0 mmol/kg/day IV in divided doses
- Potassium: Guided by serum levels and ECG changes
- Magnesium: Often requires several grams IV daily
Thiamine supplementation: Escalate to 300-500 mg IV TID if Wernicke's suspected
Fluid management: Strict input/output monitoring; consider diuresis if fluid overload
Restart nutrition: Once electrolytes stabilized, restart at even lower rate

Hack: Phosphate Repletion Calculations For severe hypophosphatemia (<0.32 mmol/L or <1.0 mg/dL):

Patients >60 kg: Give 40-80 mmol IV over 6-12 hours
Patients <60 kg: Give 0.6-1.0 mmol/kg IV over 6-12 hours
Recheck phosphate 6 hours after completion; often requires repeated dosing

Oyster: Overzealous phosphate replacement can cause hypocalcemia. Monitor calcium and treat symptomatic hypocalcemia with calcium supplementation. Avoid administering calcium and phosphate simultaneously in IV lines (precipitation risk).

Integrative Approach: Putting It All Together

Week 1 Nutrition Strategy for Typical ICU Patient

Day 1-2: Hemodynamic stabilization; trophic EN (10-20 mL/hr) Day 3-7: Permissive underfeeding (50-70% energy target, 1.2-1.5 g/kg protein) Day 7-10: Transition to full feeding as patient stabilizes

Special Considerations:

Screen for refeeding risk at admission
No routine immunonutrition supplementation in established sepsis/ARDS
Consider IC when available
Protein prioritization throughout

Decision Algorithm for Immunonutrition

Patient Population?
│
├─ Pre-op high-risk surgery → Immune-enhancing formula (arginine + omega-3)
│
├─ Trauma (no organ failure) → Consider enteral glutamine
│
├─ Severe sepsis/ARDS/MOF → Standard high-protein formula (NO immunonutrition)
│
└─ Burns >20% TBSA → Consider enteral glutamine

Refeeding Risk Mitigation Checklist

☐ Risk assessment completed (NICE criteria + ICU factors)
☐ Baseline electrolytes obtained
☐ Thiamine 100-300 mg IV ordered BEFORE feeding
☐ Electrolytes repleted to target ranges
☐ Conservative starting rate calculated (10-15 kcal/kg/day for high-risk)
☐ Monitoring schedule established (labs q6-12h × 48h)
☐ Advancement protocol defined

Conclusion

Contemporary critical care nutrition requires clinicians to abandon outdated dogmas and embrace nuanced, evidence-based approaches. Permissive underfeeding during acute illness respects the metabolic reality of critical illness while avoiding complications of overfeeding. The immunonutrition story teaches us that "more is not always better" and context matters profoundly—the same intervention may benefit surgical patients but harm those with established multiorgan failure. Refeeding syndrome, though preventable, demands systematic risk assessment, cautious reintroduction of nutrition, and vigilant monitoring.

The art of ICU nutrition lies in recognizing that critically ill patients traverse distinct metabolic phases—acute catabolic stress, stabilization, and anabolic recovery—each requiring tailored nutritional strategies. By integrating these principles with individualized patient assessment, critical care practitioners can optimize nutrition therapy as a therapeutic intervention rather than mere supportive care.

Key Takeaways

Permissive underfeeding (40-70% of target) in the acute phase (days 1-7) is safe and potentially beneficial
Protein should not be restricted even during permissive underfeeding; target 1.2-2.0 g/kg/day
Avoid routine immunonutrition (glutamine, omega-3s) in established sepsis and ARDS
Consider immune-enhancing formulas only in perioperative high-risk surgical patients
Screen all ICU admissions for refeeding risk using validated criteria
Always administer thiamine BEFORE starting nutrition in high-risk patients
"Start low, go slow" in refeeding—initial rate of 10-15 kcal/kg/day for high-risk patients
Monitor phosphate as the sentinel electrolyte for refeeding syndrome

References

Arabi YM, Aldawood AS, Haddad SH, et al. Permissive underfeeding or standard enteral feeding in critically ill adults. N Engl J Med. 2015;372(25):2398-2408.
Casaer MP, Mesotten D, Hermans G, et al. Early versus late parenteral nutrition in critically ill adults. N Engl J Med. 2011;365(6):506-517.
Hermans G, Casaer MP, Clerckx B, et al. Effect of tolerating macronutrient deficit on the development of intensive-care unit acquired weakness: a subanalysis of the EPaNIC trial. Lancet Respir Med. 2013;1(8):621-629.
Allingstrup MJ, Kondrup J, Wiis J, et al. Early goal-directed nutrition versus standard of care in adult intensive care patients: the single-centre, randomised, outcome assessor-blinded EAT-ICU trial. Intensive Care Med. 2017;43(11):1637-1647.
Marik PE, Hooper MH. Normocaloric versus hypocaloric feeding on the outcomes of ICU patients: a systematic review and meta-analysis. Intensive Care Med. 2016;42(3):316-323.
Singer P, Blaser AR, Berger MM, et al. ESPEN guideline on clinical nutrition in the intensive care unit. Clin Nutr. 2019;38(1):48-79.
Choban P, Dickerson R, Malone A, et al. A.S.P.E.N. Clinical Guidelines: nutrition support of hospitalized adult patients with obesity. JPEN J Parenter Enteral Nutr. 2013;37(6):714-744.
Weijs PJ, Looijaard WG, Beishuizen A, et al. Early high protein intake is associated with low mortality and energy overfeeding with high mortality in non-septic mechanically ventilated critically ill patients. Crit Care. 2014;18(6):701.
Heyland D, Muscedere J, Wischmeyer PE, et al. A randomized trial of glutamine and antioxidants in critically ill patients. N Engl J Med. 2013;368(16):1489-1497.
Wischmeyer PE, Dhaliwal R, McCall M, et al. Parenteral glutamine supplementation in critical illness: a systematic review. Crit Care. 2014;18(2):R76.
McClave SA, Taylor BE, Martindale RG, et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr. 2016;40(2):159-211.
Wischmeyer PE, Dhaliwal R, McCall M, et al. The role of glutamine in critical illness: meta-analysis and systematic review of the evidence. Crit Care Med. 2014;42(10):2292-2300.
Rice TW, Wheeler AP, Thompson BT, et al. Enteral omega-3 fatty acid, gamma-linolenic acid, and antioxidant supplementation in acute lung injury. JAMA. 2011;306(14):1574-1581.
Dushianthan A, Cusack R, Burgess VA, et al. Immunonutrition for acute respiratory distress syndrome (ARDS) in adults. Cochrane Database Syst Rev. 2019;1(1):CD012041.
Manzanares W, Langlois PL, Dhaliwal R, et al. Intravenous fish oil lipid emulsions in critically ill patients: an updated systematic review and meta-analysis. Crit Care. 2015;19:167.
National Institute for Health and Care Excellence. Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition. NICE Clinical Guideline 32. 2017.

Conflicts of Interest: None declared.

Acknowledgments: The author thanks the critical care nutrition teams whose clinical questions and challenges inspired this review.

For correspondence and continuing education resources on critical care nutrition, readers are encouraged to consult the ASPEN and ESPEN websites and guidelines, which are regularly updated as new evidence emerges.